<DOC>
	<DOCNO>NCT00409383</DOCNO>
	<brief_summary>This study design evaluate safety , efficacy , pharmacokinetics , pharmacodynamics combination treatment Temodar® , Genasense® , Abraxane® chemotherapy-naïve subject advance melanoma normal lactate dehydrogenase ( LDH ) .</brief_summary>
	<brief_title>Abraxane Temodar Plus Genasense Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Subjects progressive , unresectable , advanced melanoma consider candidate systemic treatment chemotherapy Subjects measurable disease , Eastern Cooperative Oncology Group Performance Status less equal 2 , serum LDH le equal 1.1 time upper limit normal , previously receive cytotoxic chemotherapy Prior immunotherapy , radiotherapy , cytokine , biologic , vaccine therapy permit adjuvant and/or metastatic set Prior treatment cytotoxic chemotherapy , include regional perfusion , Genasense® ( oblimersen sodium ) Injection Nonmeasurable disease History presence brain metastasis leptomeningeal disease Significant medical disease cancer Known human immunodeficiency virus infection Pregnant lactate Known hypersensitivity temozolomide , phosphorothioatecontaining oligonucleotides , product contain human albumin Use experimental therapy within 3 week prior baseline evaluation , Other anticancer treatment ( chemotherapy , radiation , biologic investigational therapy ) receive therapy study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Advanced Melanoma</keyword>
	<keyword>Normal baseline LDH</keyword>
	<keyword>Chemotherapy naive</keyword>
</DOC>